Pricing and Reimbursement

Two articles, published in the Journal of Comparative Effectiveness Research, explore the use of real-world evidence for coverage and formulary decisions.

Multi-Indication Pricing: Practical Solutions and Steps to Move Forward. A summary of an HTAi panel session.

OHE staff recently attended the ISPOR Europe conference in Barcelona. In this blog post, we share a selection of our presentations.

OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.

OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia. The seminar will discuss the impact of the pan-Canadian Pharmaceutical Alliance “tiered pricing” framework (a flexible 'price-cap' regulation) on generic entry, the resulting drug expenditure levels from a drug plans’ perspective and the implications of price-capping policies on drug shortages.

OHE presented at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare, held October 2018.

A new publication in the European Journal of Health Economics identifies potential challenges of ATMPs in view of current health technology assessment (HTA) methodology and explores potential solutions to these challenges. Three key topics are explored: uncertainty, discounting, and health outcomes and value. A series of recommendations are proposed.

Orphan drugs inherently face a number of challenges in their development and value assessment. In this blog post, we describe the Mechanism of Coordinated Action (MoCA) initiative, and discuss why it can be beneficial to all parties involved and how it can improve decision making for – and access to – orphan drugs in European countries.

OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

Pages

Subscribe to RSS - Pricing and Reimbursement